PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26022F0200Iclusig ponatinib 30mg TAB ITEM — Millennium Pharmaceuticals, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Apr 28, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

260-Network Contract Office 20 (36C260)

Awarding office

Millennium Pharmaceuticals, Inc

Recipient

Apr 28, 2023

PoP end

$160K

Obligated

$374K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Millennium Pharmaceuticals, Inc — $90

Contract facts

Federal

Contract number36C26022F0200

Also listed as36C260-22-F-0200

Also listed as36F79718D0586-36C26022F0200

Agency260-Network Contract Office 20 (36C260)

Awarding office260-Network Contract Office 20 (36C260)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentMillennium Pharmaceuticals, Inc

CAGE3FLV7

UEIENNFDLWFC6L1

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0586

Place of performanceCAMBRIDGE MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startApr 29, 2022

PoP end (current)Apr 28, 2023

Obligated$160K

Current value$374K

Potential value$374K

PONATINIB (ICLUSIG) 30MG TAB ITEM # 63020-0533-300 is a federal award for 260-Network Contract Office 20 (36C260) held by Millennium Pharmaceuticals, Inc. Estimated value $374K ($160K obligated). Current period of performance ends Apr 28, 2023. Last award drew 1 bidder. Place of performance: CAMBRIDGE MA.

PONATINIB (ICLUSIG) 30MG TAB ITEM # 63020-0533-300

Recompete timing

Public

● Past PoP end (1211 days ago)

Current PoP ended Apr 28, 2023 (1211 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26022F0200?

36C26022F0200 (Iclusig ponatinib 30mg TAB ITEM) is a 260-Network Contract Office 20 (36C260) award with a potential value of $374K, currently held by Millennium Pharmaceuticals, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C260-22-F-0200?

36C260-22-F-0200 is the dashed form of PIID 36C26022F0200 (Iclusig ponatinib 30mg TAB ITEM), held by Millennium Pharmaceuticals, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26022F0200?

260-Network Contract Office 20 (36C260) awarded 36C26022F0200 to Millennium Pharmaceuticals, Inc (potential $374K).

Who is the incumbent on 36C26022F0200?

Millennium Pharmaceuticals, Inc is the incumbent. The current period of performance ends Apr 28, 2023.

When does Millennium Pharmaceuticals, Inc’s 36C26022F0200 come up for recompete?

SCOUT tracks a period-of-performance end of Apr 28, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 22, 2023 · refreshed monthly